Kwangdong Pharmaceutical Joins the 'KRW 1 Trillion Club' for the First Time with KRW 1.6 Trillion in Revenue
Renewal of Samdasoo Contract and Introduction of New Drugs
Expanding the Business Portfolio
Kwangdong Pharmaceutical announced on March 26 that it held its 53rd Annual General Meeting of Shareholders in Gwacheon, Gyeonggi Province, and approved the agenda items as originally proposed, including the approval of financial statements, appointment of directors, and amendments to the articles of incorporation.
At the 53rd Annual General Meeting of Kwangdong Pharmaceutical, CEO Sangyoung Park is delivering his greeting. Kwangdong Pharmaceutical
View original imageOn a separate basis, the company’s revenue last year reached KRW 1.011 trillion, surpassing KRW 1 trillion for the first time since its founding. On a consolidated basis, revenue was KRW 1.6595 trillion. Operating profit on a separate basis was approximately KRW 30.6 billion.
The company highlighted the renewal of its sales consignment contract for Jeju Samdasoo and the securing of new drug pipelines as major achievements. It also signed an exclusive domestic contract for the retinitis pigmentosa treatment candidate 'OCU400.'
This shareholders’ meeting also included measures to improve corporate governance, such as formalizing the independent director system and establishing new committees through amendments to the articles of incorporation.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Park Sangyoung, CEO of Kwangdong Pharmaceutical, stated, "The year 2026 will be a crucial turning point as we begin to fully realize the synergies from relocating to our new headquarters in Gwacheon. We will continue to identify business opportunities that generate both external growth and profitability, as well as future value, in order to maximize shareholder value."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.